8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Hasan I, Jahan MR, Islam MN, Islam MR

Bioeffects Seen

Authors not listed · 2022

Share:

This COVID-19 treatment study was incorrectly categorized and contains no EMF research data.

Plain English Summary

Summary written for general audiences

This study appears to be misclassified in the EMF database - it actually examined COVID-19 treatments using monoclonal antibodies (casirivimab and imdevimab) in hospitalized patients. The research found these antibodies reduced death rates by 21% in patients without prior COVID antibodies, but showed no benefit in patients who already had antibodies from previous infection or vaccination.

Why This Matters

This study has been incorrectly categorized in our EMF research database. The research actually evaluated monoclonal antibody treatments for COVID-19 patients and contains no electromagnetic field exposure data whatsoever. This highlights an important issue in EMF research databases - proper categorization and quality control are essential for maintaining scientific credibility.

While this particular study doesn't contribute to our understanding of EMF health effects, it serves as a reminder that readers should always verify the actual content of research studies. The EMF research field already faces enough skepticism without database errors that could undermine legitimate scientific inquiry into electromagnetic field health effects.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2022). Hasan I, Jahan MR, Islam MN, Islam MR.
Show BibTeX
@article{hasan_i_jahan_mr_islam_mn_islam_mr_ce3262,
  author = {Unknown},
  title = {Hasan I, Jahan MR, Islam MN, Islam MR},
  year = {2022},
  doi = {10.1016/S0140-6736(22)00163-5},
  
}
DOI: 10.1016/S0140-6736(22)00163-5PubMed: 35151397

Quick Questions About This Study

This appears to be a database categorization error. The study examined monoclonal antibody treatments for COVID-19 patients and contains no electromagnetic field research or data whatsoever.
The study tested casirivimab and imdevimab antibody treatments in 9,785 hospitalized COVID-19 patients across 127 UK hospitals, measuring 28-day mortality rates compared to standard care.
Yes, but only in patients without existing COVID antibodies. The treatment reduced death rates by 21% in seronegative patients but showed no benefit in those with prior antibodies.
The RECOVERY trial enrolled 9,785 eligible patients, with 4,839 receiving the antibody treatment plus usual care and 4,946 receiving usual care alone between September 2020 and May 2021.
No significant safety issues were found. There were no treatment-related deaths and only seven patients (<1%) experienced serious adverse reactions believed related to the antibody combination treatment.